Patent 12116589 was granted and assigned to Voyager Therapeutics on October, 2024 by the United States Patent and Trademark Office.
The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).